Fludarabine-Based Conditioning Secures Engraftment of Second Hematopoietic Stem Cell Allografts (HSCT) in the Treatment of Initial Graft Failure Joseph.

Slides:

Advertisements

Similar presentations

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation Patrick.

Advertisements

The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Norovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Incidence, Risk Factors, and Outcome Joseph Delano F. Robles, Daniel.

The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.

How to Treat MDS without Stem Cell Transplantation

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Low Dose Unfractionated Heparin (UFH) Prophylaxis Is a Feasible Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) after Myeloablative.

Adenovirus Viremia and Disease: Comparison of T Cell–Depleted and Conventional Hematopoietic Stem Cell Transplantation Recipients from a Single Institution

T Cell–Depleted Stem Cell Transplantation for Adults with High-Risk Acute Lymphoblastic Leukemia: Long-Term Survival for Patients in First Complete Remission.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

A Novel Reduced-Intensity Conditioning Regimen Induces a High Incidence of Sustained Donor-Derived Neutrophil and Platelet Engraftment after Double-Unit.

Response to Pneumococcal (PNCRM7) and Haemophilus Influenzae Conjugate Vaccines (HIB) in Pediatric and Adult Recipients of an Allogeneic Hematopoietic.

Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-

Combining the Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Provides a Comprehensive Prognostic Model for.

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Edward Copelan, James T. Casper, Shelly L. Carter, Jo-Anne H

Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival Sangeeta R. Hingorani, Kristy Seidel,

Sabina Kersting, Leo F. Verdonck

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Frequent Human Herpesvirus-6 Viremia But Low Incidence of Encephalitis in Double- Unit Cord Blood Recipients Transplanted Without Antithymocyte Globulin

High Progression-Free Survival (PFS) in Adult Double Unit Cord Blood (dCB) Transplant Recipients with High Risk Disease after a Novel Intermediate Intensity.

Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord.

NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report.

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

The Role of Post-Remission Chemotherapy before T-Cell Depleted Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia in First Complete Remission

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma Jessica Rueff, Michael Medinger,

Busulfan-Dependent Hepatotoxicity of Antithymocyte Globulin Formulations During Conditioning for Hematopoietic Stem Cell Transplantation Walter J.F.M.

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

John R. Wingard, M. D. , Alan K. Leahigh, Dennis Confer, M. D

Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation Jan Storek,

Availability of Cord Blood Extends Allogeneic Hematopoietic Stem Cell Transplant Access to Racial and Ethnic Minorities Juliet N. Barker, Courtney E.

Kasiani C. Myers, Stella M. Davies

Infections Are the Major Cause of Non Relapse Mortality (NRM) after T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplantation for Advanced.

Graft-Versus Host Disease (GVHD Status and Severity Mediate Late Effects of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in a 1-Year Landmark.

Long-Term Prognosis Among 1-Year Survivors of Ex Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation: A Landmark Analysis Christina.

Fluconazole Coadministration Concurrent with Cyclophosphamide Conditioning May Reduce Regimen-Related Toxicity Postmyeloablative Hematopoietic Cell Transplantation

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation Has Unique Features and an Association with Engrafting Unit-to-Recipient HLA Match

Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Willis H. Navarro, Fausto R.

Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence Keshav.

Analysis of Hematopoietic Cell Transplants Using Plasma-Depleted Cord Blood Products That Are Not Red Blood Cell Reduced Robert Chow, Auayporn Nademanee,

Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.

Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa Barbara.

Steven M. Trifilio, Judy Pi, Jayesh Mehta

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic Syndromes Bartlomiej M. Getta, Ashwin Kishtagari,

Clinical Strategies to Enhance Posttransplant Immune Reconstitution

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation Patrick.

Once-Daily Intravenous Busulfan with Therapeutic Drug Monitoring Compared to Conventional Oral Busulfan Improves Survival and Engraftment in Children.

What is quality in a transplant program?

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, and Clinical Significance Deborah.

CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50.

Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving.

Blood and Marrow Transplant Handbook

Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Cytomegalovirus Infection after CD34+-Selected Hematopoietic Cell Transplantation Yao-Ting Huang, Dionysios Neofytos, Julia Foldi, Seong Jin Kim, Molly.

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based.

Early Fluid Overload is a Serious Toxicity Associated with an Increased Risk of Non- Relapse Mortality after Ex-Vivo CD34-Selected Allogeneic Hematopoietic.

Megadose CD34+ Cell Grafts Improve Recovery of T Cell Engraftment but not B Cell Immunity in Patients with Severe Combined Immunodeficiency Disease Undergoing.

Intravenous Busulfan and Melphalan, Tacrolimus, and Short-Course Methotrexate Followed by Unmodified HLA-Matched Related or Unrelated Hematopoietic Stem.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Reduced Late Mortality Risk Contributes to Similar Survival after Double-Unit Cord Blood Transplantation Compared with Related and Unrelated Donor Hematopoietic.

Presentation transcript:

Fludarabine-Based Conditioning Secures Engraftment of Second Hematopoietic Stem Cell Allografts (HSCT) in the Treatment of Initial Graft Failure Joseph H. Chewning, Hugo Castro-Malaspina, Ann Jakubowski, Nancy A. Kernan, Esperanza B. Papadopoulos, Trudy N. Small, Glenn Heller, Katharine C. Hsu, Miguel A. Perales, Marcel R.M. van den Brink, James W. Young, Susan E. Prockop, Nancy H. Collins, Richard J. O’Reilly, Farid Boulad Biology of Blood and Marrow Transplantation Volume 13, Issue 11, Pages 1313-1323 (November 2007) DOI: 10.1016/j.bbmt.2007.07.006 Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Schema for the most frequently administered cytoreduction regimen. Chemotherapeutic agents and ATG are displayed as a box and shown above the corresponding days these agents were administered. FLU indicates fludarabine and CY indicates cyclophosphamide. The HSCT-2 box indicates the administration of the second stem cell graft and is shown above the day of transplant (day 0). Biology of Blood and Marrow Transplantation 2007 13, 1313-1323DOI: (10.1016/j.bbmt.2007.07.006) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Kaplan-Meier probability of overall (A) and disease-free (B) survival by age following second HSCT. Biology of Blood and Marrow Transplantation 2007 13, 1313-1323DOI: (10.1016/j.bbmt.2007.07.006) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions